Live Analyst Rating Changes 1525 upgrades, downgrades & price-target moves · freshest Wall Street data, updated daily View live feed →
Analyst Tracker/Michael W. Freeman
RJ
Michael W. Freeman
Raymond James
Wall Street Analyst
Not yet ranked — too few measurable calls.
0%
Success Rate
-27.0%
Average Return
0 of 1 calls profitable · -51.1% vs benchmark
📈 Across the calls we could measure, roughly 0% of Michael W. Freeman's ratings turned a profit when each position was held for 1 year — averaging -27.0% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

15 Buy 2 Hold 0 Sell
Michael's Stock Coverage 10 ratings · 2026-06-20
Company Date Position Consensus ⓘ Price Target ⓘ 1-Yr Return
TSE:AIDX
HEALWELL AI
 Mar 25, 2026 BUY Strong Buy
+190.9% avg upside
8 analysts
$2.50
212.43% Upside
 ·
TSE:HLS
HLS Therapeutics Inc
 Nov 18, 2025 BUY Strong Buy
+107.1% avg upside
4 analysts
$7.00
61.31% Upside
 ·
TSE:WELL
WELL Health Technologies Corp
 Nov 06, 2025 BUY Strong Buy
+59.1% avg upside
9 analysts
 — ·
TSE:PRN
Profound Medical
 Oct 08, 2025 BUY Strong Buy
+96.1% avg upside
11 analysts
$15.40
60.29% Upside
 ·
TSE:MDP
Medexus Pharmaceuticals Inc
 Aug 14, 2025 BUY Strong Buy
+31.8% avg upside
5 analysts
$8.00
90.38% Upside
 ·
TSE:VHI
Vitalhub
 Aug 12, 2025 BUY Strong Buy
+92.4% avg upside
8 analysts
$15.00
112.68% Upside
 ·
TSE:BHC
Bausch Health Companies
 Aug 05, 2025 HOLD Buy
+807.0% avg upside
29 analysts
$11.20
70.38% Upside
 ·
NGEN
NervGen Pharma
 Jun 11, 2025 BUY Strong Buy
+358.7% avg upside
8 analysts
$4.29
94.85% Upside
 -27.0%
TSE:GUD
Knight Therapeutics
 Mar 12, 2025 BUY Strong Buy
-10.8% avg upside
7 analysts
$8.00
13.66% Downside
 ·
TSE:PINK
Perimeter Medical Imaging AI
 Nov 18, 2024 BUY Strong Buy
+836.3% avg upside
4 analysts
$1.50
408.49% Upside
 ·
🔒 5 more ratings — with price targets, crowd consensus and our measured returns.
Sign in free to unlock See Pro plans
Free account unlocks every analyst's full coverage table.
Michael W. Freeman — Frequently Asked Questions
How accurate are Michael W. Freeman's stock ratings?
Based on the calls 13Foresight could measure, about 0% of Michael's ratings were profitable over a one-year hold, with an average return of -27.0% per rating, or -50.8% versus the S&P 500. We score every analyst the same way, from historical prices.
How is Michael ranked on 13Foresight?
Michael W. Freeman is currently ranked unranked . Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.
Which stocks does Michael cover?
Michael most recently has ratings on TSE:AIDX, TSE:HLS, TSE:WELL, TSE:PRN, TSE:MDP, TSE:VHI, TSE:BHC, NGEN, TSE:GUD, TSE:PINK. See the full coverage table above for positions, price targets and our measured returns.
Where can I see other analyst ratings?
Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.